Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Change in Acquisitions & Divestments for 11 consecutive years, with $99.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 70.15% year-over-year to $99.3 million; the TTM figure through Mar 2026 stood at $293.4 million (up 17.86% YoY), while the FY2025 annual figure was $252.5 million, down 3.13% from the prior year.
• Change in Acquisitions & Divestments improved to $99.3 million in Q1 2026 per RYTM's latest filing, from $51.6 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $124.5 million in Q2 2023 and bottomed at $45.3 million in Q3 2024.
• Historically, Change in Acquisitions & Divestments has averaged $73.6 million across 5 years, with a median of $63.3 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments plunged 60.76% — and 2023, when it jumped 144.12%.
• Rhythm Pharmaceuticals' Change in Acquisitions & Divestments stood at $59.6 million in 2022, then climbed by 6.12% to $63.3 million in 2023, then surged by 38.3% to $87.5 million in 2024, then tumbled by 41.0% to $51.6 million in 2025, then soared by 92.17% to $99.3 million in 2026.
• Business Quant data shows RYTM's Change in Acquisitions & Divestments at $99.3 million in Q1 2026, $51.6 million in Q4 2025, and $61.5 million in Q3 2025.